

AMENDMENTS TO THE CLAIMS

1. (Withdrawn) A composition for increasing a body height of an individual, comprising a guanylyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality.
2. (Withdrawn) The composition of claim 1, for use in a patient with short stature.
3. (Withdrawn) The composition of claim 1, for use in an individual other than patients with short stature.
4. (Withdrawn) The composition of claim 1, wherein the increase in body height is extension of cartilage bones.
5. (Withdrawn) The composition of claim 1, wherein the increase in body height is extension of femora, tibiae, radiuses, and/or ulnae.
6. (Withdrawn) The composition of claim 1, wherein the activator is a peptide.
7. (Withdrawn) The composition of claim 6, wherein the peptide is type C natriuretic peptide (CNP) or a derivative thereof.
8. (Withdrawn) The composition of claim 7, wherein the CNP is CNP-22 or CNP-53 from mammals including human, or birds.
9. (Withdrawn) The composition of claim 7, wherein the CNP is CNP-22 of SEQ ID NO: 1 or CNP-53 of SEQ ID NO: 2.

10. (Withdrawn) The composition of claim 7, wherein the derivative has a deletion, substitution or addition of one or several amino acids in the amino acid sequence of SEQ ID NO: 1 or 2, while possessing a CNP activity.

11. (Currently Amended) A method for increasing a body height of an individual free from fibroblast growth factor receptor 3, (FGFR3) abnormality, comprising administering systemically C-type natriuretic peptide (CNP) or a derivative thereof activating GC-B to increase the body height in the individual, an individual free from FGFR3 abnormality

wherein the individual has growth cartilage layers,

wherein the derivative comprises a deletion, substitution or addition of between 1 to 10 amino acids in the amino acid sequence of CNP, while possessing a CNP activity, and comprises the following peptide sequence:

(A)-(B)-(C)-Gly-(D)-(E)-(F)-Asp-Arg-Ile-Gly-(G)-(H)-Ser-

(I)-(J)-Gly-(B)-(K)

wherein (A) represents H-, H-Gly, H-Lys-Gly, H-Ser-Lys-Gly, H-Leu-Ser-Lys-Gly, H-Gly-Leu-Ser-Lys-Gly, H-Ser, H-Ser-Ser, H-Arg-Ser-Ser, H-Arg-Arg-Ser-Ser, H-Leu-Arg-Arg-Ser-Ser, or H-Ser-Leu-Arg-Arg-Ser-Ser;

(B) represents H-Cys;

(C) represents Phe, pCl-Phe, pF-Phe, or Cha;

(D) represents Ile, Val, or Leu;

(E) represents Lys, Leu, or Met;

(F) represents Leu, Ile, Ala, or Val;

(G) represents Ser, Gly, Thr, Asn, or Ala;

(H) represents Met, Ala, Trp, His, Lys, Ser, Gly, or Gln;

(I) represents Gly, Lys, Ala, or Leu;

(J) represents Leu or Met;

(K) represents -OH, -Asn-OH, -Asn-Ser-OH, -Asn-Ser-Phe-OH, -Asn-Ser-Phe-Arg-OH, or -Asn-Ser-Phe-Arg-Tyr-OH; and

the symbol "... " between (B) and (B) represents a disulfide bond.

12. (Original) The method of claim 11, wherein the increase in body height is extension of cartilage bones.

13. (Currently Amended) The method of claim 11, wherein the increase in body height is extension of femora, tibiae, radiuses, and/or or ulnae.

14. (Cancelled).

15. (Currently Amended) The method of claim[[14]] 11, wherein the CNP is CNP-22 or CNP-53 from mammals, ~~including human, or birds.~~

16. (Currently Amended) The method of claim[[14]] 11, wherein the CNP is CNP-22 of SEQ ID NO: 1 or CNP-53 of SEQ ID NO: 2.

17. (Cancelled).

18. (Withdrawn) A method for screening an agent for increasing the body height of an individual, comprising screening candidate agents for an agent for increasing the body height using the activity of GC-B as an indication.

19. (Withdrawn) The method of claim 18, which comprises preparing cultured cells that express GC-B or cells from articular chondrocytes, culturing the cells in the presence of a candidate agent, and screening candidate agents for an agent for increasing the body height of an individual using the activity of GC-B in the cells as an indication.

20. (Withdrawn) The method of claim 18, wherein the activity of GC-B is determined as an amount of produced intracellular cGMP.

21. (Withdrawn) The method of claim 18, wherein it comprises preparing a cultured cell line that has been forced to express GC-B, culturing the cell line in the presence or absence of a test substance, determining an amount of intracellular cGMP produced in the cell line, and screening candidate agents for an agent for increasing body heights using the difference, as an indication, in amounts of intracellular cGMP produced in the presence and absence of the test substance.

22. (Currently Amended) A method for extending a cartilage bone free from FGFR3 abnormality in an individual, comprising administering systemically CNP or a derivative thereof to activate guanyl cyclase B-activating GC-B (GC-B) in the individual,

wherein the individual has growth cartilage layers,

wherein the derivative comprises a deletion, substitution or addition of between 1 to 10 amino acids in the amino acid sequence of CNP, while possessing a CNP activity, and comprises the following peptide sequence:

(A)-(B)-(C)-Gly-(D)-(E)-(F)-Asp-Arg-Ile-Gly-(G)-(H)-Ser-

(I)-(J)-Gly-(B)-(K)

wherein (A) represents H-, H-Gly, H-Lys-Gly, H-Ser-Lys-Gly, H-Leu-Ser-Lys-Gly, H-Gly-Leu-Ser-Lys-Gly, H-Ser, H-Ser-Ser, H-Arg-Ser-Ser, H-Arg-Arg-Ser-Ser, H-Leu-Arg-Arg-Ser-Ser, or H-Ser-Leu-Arg-Arg-Ser-Ser;

(B) represents H-Cys;

(C) represents Phe, pCl-Phe, pF-Phe, or Cha;

(D) represents Ile, Val, or Leu;

(E) represents Lys, Leu, or Met;

(F) represents Leu, Ile, Ala, or Val;

(G) represents Ser, Gly, Thr, Asn, or Ala;

(H) represents Met, Ala, Trp, His, Lys, Ser, Gly, or Gln;

(I) represents Gly, Lys, Ala, or Leu;

(J) represents Leu or Met;

(K) represents -OH, -Asn-OH, -Asn-Ser-OH, -Asn-Ser-Phe-OH, -Asn-Ser-Phe-Arg-OH, or -
Asn-Ser-Phe-Arg-Tyr-OH; and
the symbol "... " between (B) and (B) represents a disulfide bond.

23. (New) The method of claim 11, wherein the individual is a patient with short stature disease.